Severely ill pediatric patients with Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) who suffered from multiple organ involvement in the early stage
- PMID: 33205220
- DOI: 10.1007/s00467-020-04829-4
Severely ill pediatric patients with Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) who suffered from multiple organ involvement in the early stage
Abstract
Background: Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome (STEC-HUS) is the main cause of pediatric acute kidney injury (AKI) in Argentina. Endothelial injury is the trigger event in the microangiopathic process. The host inflammatory response to toxin and E. coli lipopolysaccharide (LPS) is involved in disease pathophysiology.
Methods: This retrospective study describes pediatric STEC-HUS patients with multiorgan involvement at the initial phase of disease. A retrospective study of critically ill HUS patients with evidence of E. coli infection was conducted through a period of 15 years.
Results: Forty-four patients 35.4 ± 4.1 months were admitted to the intensive care unit for 21 ± 2 days. Mechanical ventilation was required in 41 patients, early inotropic support in 37, and 28 developed septic shock. Forty-one patients required kidney replacement therapy for 12 ± 1 days. Forty-one patients showed neurological dysfunction. Dilated cardiomyopathy was demonstrated in 3 patients, left ventricular systolic dysfunction in 4, and hypertension in 17. Four patients had pulmonary hemorrhage, and acute respiratory distress syndrome in 2. Colectomy for transmural colonic necrosis was performed in 3 patients. Thirty-seven patients were treated with therapeutic plasma exchange, and 28 patients received methylprednisolone (10 mg/kg for 3 days). Of the surviving 32 patients, neurological sequelae were seen in 11 and chronic kidney failure in 5.
Conclusions: Severe clinical outcome at onset suggests an amplified inflammatory response after exposure to Shiga toxin and/or E. coli LPS. STEC-HUS associated with severe neurological involvement, hemodynamic instability, and AKI requires intensive care and focused therapy.
Keywords: Children; Kidney replacement therapy; Multiorgan involvement; Neurological compromise; STEC-HUS patients.
Similar articles
-
Diagnosis and Treatment for Shiga Toxin-Producing Escherichia coli Associated Hemolytic Uremic Syndrome.Toxins (Basel). 2022 Dec 23;15(1):10. doi: 10.3390/toxins15010010. Toxins (Basel). 2022. PMID: 36668830 Free PMC article. Review.
-
Outcome 10 years after Shiga toxin-producing E. coli (STEC)-associated hemolytic uremic syndrome: importance of long-term follow-up.Pediatr Nephrol. 2024 Aug;39(8):2459-2465. doi: 10.1007/s00467-024-06355-z. Epub 2024 Apr 9. Pediatr Nephrol. 2024. PMID: 38589699 Free PMC article.
-
Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS).Pediatr Nephrol. 2019 Dec;34(12):2495-2507. doi: 10.1007/s00467-018-4105-1. Epub 2018 Nov 1. Pediatr Nephrol. 2019. PMID: 30382336 Review.
-
Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008.BMC Infect Dis. 2016 Jun 13;16:285. doi: 10.1186/s12879-016-1627-7. BMC Infect Dis. 2016. PMID: 27297224 Free PMC article.
-
Acute peritoneal dialysis, complications and outcomes in 389 children with STEC-HUS: a multicenter experience.Pediatr Nephrol. 2021 Jun;36(6):1597-1606. doi: 10.1007/s00467-020-04876-x. Epub 2021 Jan 4. Pediatr Nephrol. 2021. PMID: 33394193
Cited by
-
Genetic Characterization of Intimin Gene (eae) in Clinical Shiga Toxin-Producing Escherichia coli Strains from Pediatric Patients in Finland.Toxins (Basel). 2023 Nov 23;15(12):669. doi: 10.3390/toxins15120669. Toxins (Basel). 2023. PMID: 38133173 Free PMC article.
-
Toll-like Receptor 4 in Acute Kidney Injury.Int J Mol Sci. 2023 Jan 11;24(2):1415. doi: 10.3390/ijms24021415. Int J Mol Sci. 2023. PMID: 36674930 Free PMC article. Review.
-
Diagnosis and Treatment for Shiga Toxin-Producing Escherichia coli Associated Hemolytic Uremic Syndrome.Toxins (Basel). 2022 Dec 23;15(1):10. doi: 10.3390/toxins15010010. Toxins (Basel). 2022. PMID: 36668830 Free PMC article. Review.
-
Erythropoietin in children with hemolytic uremic syndrome: a pilot randomized controlled trial.Pediatr Nephrol. 2022 Oct;37(10):2383-2392. doi: 10.1007/s00467-022-05474-9. Epub 2022 Feb 15. Pediatr Nephrol. 2022. PMID: 35166922 Clinical Trial.
-
Thrombotic microangiopathy in children.Pediatr Nephrol. 2022 Sep;37(9):1967-1980. doi: 10.1007/s00467-021-05370-8. Epub 2022 Jan 18. Pediatr Nephrol. 2022. PMID: 35041041 Free PMC article. Review.
References
-
- Oualha M, Pierrepont S, Krug P, Gitiaux C, Hubert P, Lesage F, Salomon R (2018) Postdiarrheal hemolytic and uremic syndrome with severe multiorgan involvement and associated early risk factors. Arch Pediatr 25:118–125 - PubMed
-
- Gianantonio C, Vitaco M, Mendilaharzu F, Rutty A, Mendilaharzu J (1964) The hemolytic uremic syndrome. J Pediatr 54:478–491
-
- Boletín Integrado de Vigilancia N° 344–SE 3–Enero de 2017. Available online: http://www.msal.gob.ar/images/stories/boletines/Boletin-Integrado-De-Vig...
-
- Rivas M, Sosa-Estani S, Rangel J, Caletti MG, Vallés P, Roldán CD, Balbi L, Marsano de Mollar MC, Amoedo D, Miliwebsky E, Chinen I, Hoekstra RM, Mead P, Griffin PM (2008) Risk Factors for sporadic shiga toxin–producing Escherichia coli infections in children, Argentina). Emerg Infect Dis 14:763–771 - PubMed - PMC
-
- Karmali MA, Steele BT, Petric M, Lim C (1983) Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1:619–620 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical